ライフサイエンスコーパス: deferiprone

1 r Parkin-independent mitophagy stimulated by deferiprone.

2 al sensing of anti-HIV replication drug i.e. deferiprone.

3 were coordinately affected by ciclopirox and deferiprone.

4 can be inhibited by the drugs ciclopirox and deferiprone.

5 to detect any potential protective effect of deferiprone.

6 intravenous deferoxamine, augmented by oral deferiprone.

7 proved brain distribution when compared with deferiprone.

8 and effectiveness of long-term therapy with deferiprone.

9 treated with the orally active iron chelator deferiprone (1,2 dimethyl-3-hydroxypyrid-4-one, L1) at a

10 2 early onset PD patients, were administered deferiprone, 10 or 15 mg/kg BID or placebo, for 6 months

11 Seventy-two patients were treated with deferiprone 20, 40, or 60mg/kg/day or placebo, divided i

12 One patient on deferiprone 20mg/kg/day experienced reversible neutropen

13 that, in patients with less severe disease, deferiprone 20mg/kg/day may reduce disease progression,

14 h less severe disease suggested a benefit of deferiprone 20mg/kg/day on ICARS, FARS, kinetic function

15 ing the effectiveness of the studied dose of deferiprone, 47 patients discontinued therapy, whereas 1

16 al oral placebo (deferoxamine group) or oral deferiprone 75 mg/kg per day (combined group).

17 Whereas deferiprone acts synergistically with the zinc chelator

18 iologic assessment of European outcomes with deferiprone, an oral alternative chelator available for

19 nature of its structure, DFO is larger than deferiprone and is thus less able to access some intrace

20 emoval from Tf/2N by 3-hydroxypyridin-4-one (deferiprone) and nitrilotriacetic acid (NTA) are essenti

21 nically applied medications desferrioxamine, deferiprone, and deferasirox.

22 demonstrated an acceptable safety profile of deferiprone at 20mg/kg/day for the treatment of patients

23 The only alternative treatment is oral deferiprone, but its long-term efficacy on myocardial ir

24 gnetic resonance imaging (MRI) suggests that deferiprone can unload myocardial iron faster than defer

25 and mortality in Italian subjects exposed to deferiprone compared with deferoxamine.

26 xamine (DFO) and the hydroxypiridinone (HPO) deferiprone (CP20) chelate iron as well as other metals.

27 in comparison to simple dialkyl HPOs such as Deferiprone (CP20) which cause up to 70% inhibition.

28 m cardiomyocytes exceeded that obtained with deferiprone, desferrioxamine, or deferasirox at similar

29 oxidase (HRP), via glutaraldehyde (Glu), for deferiprone detection using impedimetric technique.

30 of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including thei

31 retinal protection by the oral iron chelator deferiprone (DFP).

32 nistration of the FDA-approved iron chelator deferiprone evidenced significant reductions in tumor si

33 For both Tf/2N and Tf-FeN, iron removal by deferiprone follows simple saturation kinetics, while ir

34 iron content in 17 patients who had received deferiprone for 24 to 48 months ranged from 5.9 to 41.2

35 Twenty-six patients continued deferiprone for a mean of 39.4 months (range, 12 to 49).

36 When the patients who had received deferiprone for longer than 3 years were considered sepa

37 The deferiprone group had significantly less myocardial iron

38 ial iron (T2* <20 ms) was less common in the deferiprone group than in the desferrioxamine controls (

39 n in the desferrioxamine controls versus the deferiprone group was 5.5 (95% CI 1.2-28.8).

40 Patients receiving 20mg/kg/day of deferiprone had no significant change in FARS, similar t

41 The oral iron chelator deferiprone has been demonstrated to remove myocardial i

42 Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years.

43 s at the time of change from deferoxamine to deferiprone in either the intention-to-treat analysis or

44 assess safety, tolerability, and efficacy of deferiprone in Friedreich ataxia (FRDA).

45 ar of therapy, and led to discontinuation of deferiprone in only one patient in years 2 to 4.

46 spective study of the safety and efficacy of deferiprone in patients with thalassemia major, we have

47 orinated compounds have clear advantage over deferiprone in that they are metabolized more slowly.

48 ice or in vitro loading with zinc, abrogated deferiprone-induced murine thymocyte apoptosis.

49 Bidentate hydroxypyridinones such as deferiprone interact with intracellular zinc pools in a

50 Oral deferiprone is more effective than desferrioxamine in re

51 s study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron fro

52 hobiology, we administered the iron chelator deferiprone (L1) intraperitoneally to beta-thalassemic m

53 hepatic iron depletion: iron chelation using deferiprone (L1) versus iron-deficient diets.

54 bility of the nano Au sensor is to determine deferiprone level in spiked urine and serum samples.

55 r the beneficial effect of the iron chelator deferiprone on iron overload.

56 amine, combination treatment with additional deferiprone reduced myocardial iron and improved the eje

57 posure of murine thymocytes to either DFO or deferiprone resulted in significant reductions in the la

58 eatment of NZB/W mice with the iron chelator deferiprone significantly delayed the onset of albuminur

59 This report presents that Deferiprone, the only clinically used 3-hydroxypyridin-4

60 Deferiprone therapy was well tolerated and was associate

61 tion and mood were not adversely affected by deferiprone therapy.

62 The ability of deferiprone to preferentially access zinc pools was also

63 Although 30 mg/kg deferiprone treated patients showed a trend for improvem

64 Deferiprone-treated patients receiving 20 or 40mg/kg/day

65 itin levels in the 26 patients who continued deferiprone treatment were significantly lower than in t

66 function in 15 patients receiving long-term deferiprone treatment with 30 matched thalassaemia major

67 controlled trials shows superior efficacy of deferiprone versus deferoxamine, the superiority of comb

68 Deferiprone was well tolerated at 20mg/kg/day, whereas m

69 helators, such as EDTA, desferrioxamine, and deferiprone, were found to cause the nanoshells to degra

70 (iron-binding equivalents), as compared with deferiprone which caused 40% inhibition of the enzyme ac

71 be modulated by drugs such as ciclopirox or deferiprone, which might be repositioned to control canc

72 nano Au sensor exhibited a good response to deferiprone with a wide linear range (0.005-1000microM)

73 us deferoxamine, the superiority of combined deferiprone with deferoxamine versus deferoxamine alone,